(Q80784849)
Statements
Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineere monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors (English)
S Goel
R J Bauer
K Desai
A Bulgaru
T Iqbal
B-K Strachan
G Kim
A Kaubisch
G F Vanhove
G Goldberg